Skip to main content

Table 5 HZ as co-morbidity analyses: LOS, death rate and economic evaluation

From: Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France

  

Circulatory system

Respiratory system

Osteoarticulary system

Digestive system

Diabetes

LOS

       Median (days)

Casesa

11

12

9

8

9

 

Controlb

5

7

6

2

5

       Median difference days

6

5

3

6

4

       % rise

1.2 %

0.71 %

0.5 %

3 %

0.8 %

       Tests (Wilcoxon-Mann–Whitney)

(p values 0,05)

<0.0100

<0.0001

<0.0001

<0.0001

<0.0001

Death rate

       Deaths among cases cohorta

     
 

Death rate (%)

32/615

41/481

5/268

16/275

1/78

       Deaths among control cohortb

5.2 %

8.52 %

1.86 %

5.81 %

1.28 %

 

Death rate (%)

113/1,845

155/1,443

2/804

26/825

3/234

       Chi-square probability

(p value 0,05)

6.12 %

10.74 %

0.24 %

3.15 %

1.28 %

Hospital stay cost

       Median (€)

Cases cohorta

4,228

4,534

4,475

3,601

3,510

 

Control cohortb

3,371

3,589

3,553

1,590

2,523

       Median difference (€)

857

945

922

2,011

987

       % rise

25 %

26 %

26 %

126 %

39 %

       Tests (Wilcoxon-Mann–Whitney)

(p value 0,05)

<0.0100

<0.0001

<0.0001

<0.0001

<0.0001

  1. HZ: Herpes Zoster
  2. LOS: Length of stay
  3. aCohort of patients hospitalized with HZ in SAD
  4. bCohort of patients hospitalized without HZ in SAD